Suppr超能文献

The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.

作者信息

Lacourcière Y

机构信息

Department of Physiology and Medicine, Université de Montréal, Québec.

出版信息

Can J Cardiol. 1995 Aug;11 Suppl F:45F-48F.

PMID:7664218
Abstract

Losartan is the first of a new class of antihypertensive agents called 'angiotensin II antagonists'. It selectively and completely blocks the binding of angiotensin II at the angiotensin type 1 receptor-a unique mechanism of action different from all the other classes of antihypertensive agents. Losartan is as effective as other commonly used antihypertensive agents, but it permits convenient dosing and is better tolerated. On the strength of current data on its safety and efficacy, losartan should be considered a valuable option for many hypertension patients in whom angiotensin-converting enzyme inhibitors or calcium antagonists would be used. Although the administration of losartan produces beneficial effects and may be cost effective, long term data regarding morbidity and mortality in hypertension are needed.

摘要

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验